Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

822

Participants

Timeline

Start Date

January 3, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
AsthmaWheezing
Interventions
DRUG

Broncho-Vaxom (BV)

Active Ingredient: Lyophilised bacterial extract; Chemical Name: OM-85 BV; Strength: 3.5 mg; Excipients: bacterial extract, propyl gallate, sodium glutamate, mannitol, pregelatinised starch, magnesium stearate; Appearance: Blue and white capsule; Dosage Form: 3.5 mg capsule; Manufacturer: OM Pharma, Switzerland (OM stands for Omnia Medicamenta) Storage: Store in the original package

OTHER

Placebo

A placebo capsule will be used that will be indistinguishable from the active study drug.

Trial Locations (11)

10032

Columbia University, New York

20037

Children's National Health System, Washington D.C.

27514

University of North Carolina, Chapel Hill

30322

Emory University, Atlanta

45229

Cincinnati Children's Hospital & Medical Center, Cincinnati

63110

Washington University, St Louis

85016

Phoenix Children's Hospital, Phoenix

85724

University of Arizona, Tucson

94609

University of California San Francisco, Benioff Children's Hospital, Oakland

02115

Boston Children's Hospital, Harvard University, Boston

53792-4108

University of Wisconsin, Madison

All Listed Sponsors
lead

University of Arizona

OTHER

NCT02148796 - Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness | Biotech Hunter | Biotech Hunter